MA52174A - Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques - Google Patents

Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques

Info

Publication number
MA52174A
MA52174A MA052174A MA52174A MA52174A MA 52174 A MA52174 A MA 52174A MA 052174 A MA052174 A MA 052174A MA 52174 A MA52174 A MA 52174A MA 52174 A MA52174 A MA 52174A
Authority
MA
Morocco
Prior art keywords
chemiokin
receptor
directed against
antibodies directed
therapeutic uses
Prior art date
Application number
MA052174A
Other languages
English (en)
French (fr)
Inventor
Marc Dubourdeau
Vanessa Gauttier
Caroline Mary
Nicolas Poirier
Charlène Trilleaud
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA52174A publication Critical patent/MA52174A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA052174A 2018-04-03 2019-04-03 Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques MA52174A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305395 2018-04-03

Publications (1)

Publication Number Publication Date
MA52174A true MA52174A (fr) 2021-02-17

Family

ID=62046804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052174A MA52174A (fr) 2018-04-03 2019-04-03 Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques

Country Status (11)

Country Link
US (2) US20210147558A1 (https=)
EP (2) EP3774899A1 (https=)
JP (2) JP2021520210A (https=)
KR (2) KR102802041B1 (https=)
CN (2) CN120484119A (https=)
AU (2) AU2019247068A1 (https=)
BR (1) BR112020020118A2 (https=)
CA (1) CA3102607A1 (https=)
IL (2) IL321209A (https=)
MA (1) MA52174A (https=)
WO (1) WO2019193029A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) * 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
PH12022550844A1 (en) * 2019-10-09 2023-06-14 Ose Immunotherapeutics Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications
EP3804754A1 (en) * 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
CN120643848A (zh) 2021-01-15 2025-09-16 瑞尔科技有限公司 便携式紧急逃生装置
WO2023076329A1 (en) * 2021-10-26 2023-05-04 Thetis Pharmaceuticals Llc Compositions and methods for cancer therapy
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
US8038992B2 (en) * 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
JP5883515B2 (ja) * 2012-02-06 2016-03-15 エーエスエムエル ネザーランズ ビー．ブイ． 対象物を保持するための支持構造を備えるリソグラフィ装置及びそれに用いられる支持構造
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Also Published As

Publication number Publication date
US20210147558A1 (en) 2021-05-20
AU2019247068A1 (en) 2020-10-22
IL321209A (en) 2025-07-01
EP3774899A1 (en) 2021-02-17
IL277701A (en) 2020-11-30
AU2026200353A1 (en) 2026-03-26
JP2021520210A (ja) 2021-08-19
EP4656247A2 (en) 2025-12-03
CN112218894A (zh) 2021-01-12
CA3102607A1 (en) 2019-10-10
BR112020020118A2 (pt) 2021-02-23
KR102802041B1 (ko) 2025-04-30
CN120484119A (zh) 2025-08-15
US20240400698A1 (en) 2024-12-05
WO2019193029A1 (en) 2019-10-10
KR20250065423A (ko) 2025-05-12
EP4656247A3 (en) 2026-03-11
JP2024105648A (ja) 2024-08-06
KR20210006359A (ko) 2021-01-18

Similar Documents

Publication Publication Date Title
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3891183A4 (en) ANTI-CLAUDIN ANTIBODIES AND USES THEREOF
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3794037A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF
EP3762031A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREFORE
MA52174A (fr) Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
EP3621642A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND USES THEREOF
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND USES THEREOF
EP3383916A4 (en) Anti-cd73 antibodies and uses thereof
EP3877416A4 (en) ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF
EP3389702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3681912A4 (en) AXL SPECIFIC ANTIBODIES AND USES THEREOF
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
EP3856192A4 (en) ANTI-ALK DEGRADERS AND THERAPEUTIC USES THEREOF
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
EP3850012A4 (en) Anti-tnfrsf9 antibodies and uses thereof
EP3755714A4 (en) Anti-angiopoietin-2 antibodies and uses thereof
EP3672987A4 (en) ANTI-APELIN ANTIBODIES AND USES THEREOF
MA54469A (fr) Anticorps anti-il-27 et leurs utilisations